# NCT06741644 (NCT06741644)

> A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06741644
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: CStone Pharmaceuticals
- Conditions: Advanced Solid Tumors
- Interventions: CS2009; CS2009; Pemetrexed; Carboplatin; Paclitaxel; Etoposide; Nab-paclitaxel; Oxaliplatin; Capecitabine; Docetaxel; Leucovorin; 5-FU; Cisplatin; Gemcitabine; Irinotecan
- Enrollment: 800
- Primary outcome: [Dose Escalation] Maximum tolerated dose (MTD) of CS2009
- Primary outcome: [Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS2009
- Primary outcome: [Dose Escalation] Number of participants with adverse events (AEs)
- Primary outcome: [Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06741644